Triangle Research Labs

Triangle Research Labs (TRL) provided human and animal cryopreserved hepatocytes, essential cellular models for in vitro research. These products enabled pharmaceutical and biotech companies to evaluate drug metabolism, drug-drug interactions, and toxicology. TRL's offerings supplied critical data, accelerating drug discovery and de-risking therapeutic candidate selection.

TRL was founded in October 2011 as a joint venture by The Hamner Institutes for Health Sciences and PBM Capital Group. This addressed a significant industry need for consistent, reliable hepatocyte products for preclinical drug testing. Paul B. Manning, Chairman and CEO of PBM Capital, leveraged his healthcare experience to establish the company.

Pharmaceutical companies, biotech firms, and contract research organizations constituted TRL's primary clientele. TRL envisioned itself as a foremost provider of in vitro hepatocyte models, facilitating the efficient development of novel therapeutic agents. The company aimed to advance drug development by equipping clients with crucial research tools for safer market introductions.

High-Level Overview

Triangle Research Labs (TRL) is a biotechnology company specializing in predictive toxicity testing and hepatocyte-based products for drug discovery and development. It screens drug compounds before clinical studies to identify toxic ones early, saving time and costs, and provides hepatocytes supporting in vitro evaluation of metabolism and drug-drug interactions.[1][2][3][4] Formed as a joint venture, TRL serves biotech, pharmaceutical companies, and research centers by offering contract research organization (CRO) services, laboratory testing, and preclinical resources, with a focus on liver toxicity and innovative predictive tools.[1][2]

Origin Story

Triangle Research Labs was established in 2011 through a joint venture between The Hamner Institutes for Health Sciences (a nonprofit in Research Triangle Park, North Carolina) and PBM Capital Group, an investment firm from Charlottesville, Virginia. The venture incorporated the contract research arm of PBM's portfolio company GigaCyte, relocating it from Connecticut to North Carolina's Research Triangle Park.[1] Leadership includes Ivin Silver (former GlaxoSmithKline director of drug metabolism), Shiloh Barfield (ex-vice president of sales at CellzDirect), and Edward LeCluyse (senior researcher at The Hamner and UNC adjunct professor), driving expertise in toxicology and drug development.[1] This collaboration emerged to advance next-generation predictive toxicology tools, combining GigaCyte's biotech resources with The Hamner's liver toxicity research.[1]

Core Differentiators

• Specialized Predictive Testing: Focuses on early-stage screening of drug compounds for toxicity, particularly liver-related, using advanced in vitro hepatocyte models to accelerate drug discovery and reduce failure rates in later stages.[1][2]
• Hepatocyte Expertise: Provides fast-growing, high-quality hepatocytes for evaluating metabolism, drug-drug interactions, and preclinical safety, positioning it as a key supplier in biotech lab services.[2][4]
• CRO Model with Proven Backing: Operates as a dedicated CRO in Research Triangle Park, leveraging joint venture synergies from PBM Capital and The Hamner for innovative science and adoption of cutting-edge tools.[1][3]
• Leadership and R&D Strength: Backed by industry veterans from GSK, CellzDirect, and academic toxicology, enabling robust research programs and customized solutions for pharma clients.[1]

Role in the Broader Tech Landscape

Triangle Research Labs rides the trend toward in vitro and predictive toxicology in biotech, addressing rising drug development costs and failure rates (often over 90% in clinical trials due to toxicity). Its timing aligns with post-2011 shifts to advanced cellular models like hepatocytes, reducing animal testing and speeding preclinical phases amid regulatory pressures for safer, faster drug pipelines.[1][2] Market forces favoring TRL include the explosive growth in biologics and small-molecule drugs, where early toxicity detection is critical, and the biotech hub status of Research Triangle Park, which amplifies its ecosystem influence through collaborations with pharma giants and startups.[1][3] By enabling quicker, cost-effective screening, TRL contributes to broader efficiency in drug discovery, potentially lowering the $2-3 billion average cost per approved drug.

Quick Take & Future Outlook

Triangle Research Labs stands as a niche enabler in preclinical biotech, with potential to expand amid AI-driven drug discovery and organ-on-chip technologies that enhance its hepatocyte platforms. Upcoming trends like personalized medicine and real-world evidence will likely boost demand for its predictive tools, evolving its role from service provider to innovator in toxicity AI models. As biotech funding rebounds, TRL's PBM backing and RTP location position it for acquisitions or partnerships, amplifying impact on safer, faster therapies—echoing its 2011 origins in cost-saving innovation.[1][2]